July 2026
Depression
What July 2026's 25 new studies found, synthesized from the papers below. All Depression research →
The synthesis
Synthesized from 22 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Depression, major depressive disorder, MDD, depressive disorder, treatment-resistant depression, then ranked by relevance.
Research published in July 2026 on depression focused heavily on rapid-acting antidepressants, particularly ketamine, esketamine, and psilocybin, with consistent evidence that these treatments produce significant short-term symptom reduction in treatment-resistant depression. However, durability, long-term safety, and optimal maintenance strategies remain unresolved, and several studies highlighted methodological limitations such as small samples, lack of blinding, and inconsistent reporting. Overall, the evidence supports acute efficacy but underscores the need for larger, longer-term trials to establish sustained benefits and safety.
Evidence by study
Direction is which way each study's own result points, not our rating of the study. All 25 matching studies were reviewed; the 22 that directly address the question are shown here.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Beyond Monoamines: Ketamine, Esketamine, and Classic Psychedelics in the Treatment of Depression 2026 | review | Supports | This review concludes that ketamine and esketamine have the strongest evidence among rapid-acting antidepressants for treatment-resistant depression, while psilocybin-assisted therapy shows promise but remains investigational. | |
| Clinical guidance on the use of esketamine nasal spray for patients with treatment resistant depression: A European Delphi consensus report. 2026 | modified Delphi panel | 30 | Supports | Expert consensus supported continuing esketamine nasal spray even with modest acute-phase improvement and advocated for dose/frequency maximization, with maintenance prolongation depending on clinical worsening during tapering and relapse risk. |
| Serum brain-derived neurotrophic factor following oral esketamine in treatment-resistant depression: Results from a randomized placebo-controlled trial. 2026 | randomized controlled trial | 54 | No effect | Repeated low-dose oral esketamine did not increase serum BDNF relative to placebo, and BDNF changes did not correlate with depression severity changes. |
| Predictors of responsiveness to ketamine: An updated systematic review of neuroimaging findings. 2026 | systematic review | Supports | This systematic review identified the anterior cingulate cortex and amygdala, along with their connectivity, as potential neuroimaging biomarkers predicting responsiveness to ketamine in major depressive disorder. | |
| Initiating dextromethorphan-bupropion extended release in patients with major depressive disorder: Delphi panel expert consensus recommendations 2026 | modified Delphi panel procedure | 10 | Supports | The panel reached consensus on 27 recommendations for initiating dextromethorphan-bupropion extended release for major depressive disorder, including its use as a first-line treatment and guidance for switching from other medications. |
| Mindfulness-based exposure and response prevention in individuals with comorbid obsessive-compulsive and major depressive disorders: a randomized controlled trial 2026 | randomized controlled trial | 54 | Supports | Mindfulness-based exposure and response prevention produced greater reductions in OCD symptom severity and greater improvements in depressive symptoms compared to standard exposure and response prevention, though the time-by-group interaction for depression was not significant. |
| From trial to clinic: psilocybin’s efficacy in routine treatment-resistant depression 2026 | observational cohort | 19 | Supports | In routine clinical practice, psilocybin treatment was associated with a substantial decrease in clinician-rated depressive symptoms, with a Montgomery-Åsberg reduction of approximately 11 points and Hedges' g ≈ 1.4. |
| The potential role of psychedelics in palliative care 2026 | review | Supports | This review reports that psychedelics can produce rapid and long-lasting antidepressant and anxiolytic effects with a low risk of serious adverse events in end-of-life patients, but notes legal restrictions hinder progress. | |
| Treatment-resistant Depression in the Post-ketamine Era: Unmet Needs beyond Rapid Response 2026 | review | Mixed | This review argues that while ketamine and esketamine have shifted unmet needs from acute response to post-response management, unresolved issues include durability, relapse prevention, functional recovery, patient selection, and long-term safety. | |
| Is the reduction in suicidal ideation and deliberate self-harm during intranasal esketamine treatment independent of antidepressant response? A secondary, longitudinal analysis of a real-world TRD cohort with and without comorbid borderline personality disorder 2026 | secondary analysis of a longitudinal cohort | Supports | The within-person reduction in suicidal ideation over six months remained statistically significant after adjusting for time-varying depressive severity, indicating an anti-suicidal effect partly independent of mood improvement. | |
| Acceptability and safety of two sequential doses of psilocybin in bipolar II depression: protocol for an open-label single-arm feasibility study. 2026 | phase II, single-arm, open-label clinical trial feasibility study | 10 | Unclear | This protocol aims to explore the acceptability, safety, and treatment preferences of psilocybin-assisted therapy in patients with bipolar II disorder struggling with suicidal ideation; no results are reported. |
| Reporting practices in psilocybin-assisted therapy trials for depression: A descriptive review and temporal overview 2026 | systematic review | Mixed | This review found inconsistent reporting practices in psilocybin-assisted therapy trials, with poor reporting of blinding success, therapist fidelity, and expectancy, and an overrepresentation of participants with previous psychedelic experiences. | |
| Enhancing plasticity to treat depression and other central nervous system diseases using event-driven pharmacology. 2026 | review | Supports | This review argues that plastogens, including ketamine and classical psychedelics, operate under an event-driven pharmacology model where transient binding induces long-lasting neuroplastic changes that outlast drug exposure. | |
| Mechanisms of mindfulness-based cognitive therapy in difficult-to-treat depression: moderation and mediation analyses from the RESPOND trial. 2026 | secondary moderation, mediation, and moderated mediation analyses of a randomized trial | 234 | Supports | Baseline depressive severity did not moderate the treatment effect of MBCT, but it moderated the indirect effect through decentering, with decentering more strongly associated with symptom reduction among those with higher baseline depression. |
| Psilocybin-induced behavioral and cellular effects. 2026 | experimental study | Supports | Psilocybin-induced c-Fos expression in the nucleus accumbens is mediated by 5-HT2A receptors in neurons and by 5-HT2B receptors in both neurons and non-neuronal cells, suggesting a role for these receptors in mood-related circuits. | |
| MDMA and Psilocybin-Assisted Therapy in Australia: Early Real-World Prescribing, Safety Monitoring and Regulatory Developments 2026 | review | Supports | Australia's regulatory pathway for MDMA and psilocybin prescriptions has grown rapidly, with authorized prescribers increasing by over 135% within six months, though they represent about 1% of the psychiatric workforce. | |
| Quick protocol for depression with intravenous ketamine. 2026 | review | Supports | This review states that intravenous ketamine is supported by guidelines for treatment-resistant depression but requires careful monitoring due to variable efficacy and side effects. | |
| Esketamine for treatment-resistant depression: Comparing two maintenance schedules in an observational real-world study 2026 | retrospective observational cohort | 65 | No effect | No significant differences in depressive symptom trajectories were observed between a front-loaded and a spaced interval-extension maintenance schedule for intranasal esketamine, though induction produced significant reductions. |
| Real-world outcomes of intranasal esketamine and intravenous ketamine induction therapy for treatment-resistant depression in a community clinic: a retrospective cohort study 2026 | retrospective cohort study | 63 | Supports | Both intranasal esketamine and intravenous ketamine produced large and clinically meaningful reductions in depression severity during induction therapy, with no significant between-group differences. |
| Treating addiction with an addictive drug: the ketamine paradox revisited 2026 | narrative review | Mixed | Ketamine combined with psychotherapy shows promising reductions in craving and increases in abstinent days for alcohol and cocaine use disorders, but effects on relapse prevention are inconsistent and the drug carries a well-established risk of misuse. | |
| Complex harmonic manifolds in mindfulness-based cognitive therapy for major depressive disorder 2026 | randomized controlled trial | 80 | Supports | Mindfulness-based cognitive therapy, compared to treatment as usual alone, was associated with greater integration of bodily and interoceptive processing regions within whole-brain manifolds and increased brain flexibility during rumination. |
| Beyond symptom reduction: DMT improves anxiety, life satisfaction, and quality of life in healthy volunteers and patients with depression 2026 | open-label clinical trial | 41 | Supports | Inhaled DMT with psychological support was associated with reduced anxiety, increased life satisfaction, and sustained improvements in quality of life in patients with treatment-resistant depression over 12 months. |
This review concludes that ketamine and esketamine have the strongest evidence among rapid-acting antidepressants for treatment-resistant depression, while psilocybin-assisted therapy shows promise but remains investigational.
review
Expert consensus supported continuing esketamine nasal spray even with modest acute-phase improvement and advocated for dose/frequency maximization, with maintenance prolongation depending on clinical worsening during tapering and relapse risk.
modified Delphi panel Sample size: 30
Repeated low-dose oral esketamine did not increase serum BDNF relative to placebo, and BDNF changes did not correlate with depression severity changes.
randomized controlled trial Sample size: 54
This systematic review identified the anterior cingulate cortex and amygdala, along with their connectivity, as potential neuroimaging biomarkers predicting responsiveness to ketamine in major depressive disorder.
systematic review
The panel reached consensus on 27 recommendations for initiating dextromethorphan-bupropion extended release for major depressive disorder, including its use as a first-line treatment and guidance for switching from other medications.
modified Delphi panel procedure Sample size: 10
Mindfulness-based exposure and response prevention produced greater reductions in OCD symptom severity and greater improvements in depressive symptoms compared to standard exposure and response prevention, though the time-by-group interaction for depression was not significant.
randomized controlled trial Sample size: 54
In routine clinical practice, psilocybin treatment was associated with a substantial decrease in clinician-rated depressive symptoms, with a Montgomery-Åsberg reduction of approximately 11 points and Hedges' g ≈ 1.4.
observational cohort Sample size: 19
This review reports that psychedelics can produce rapid and long-lasting antidepressant and anxiolytic effects with a low risk of serious adverse events in end-of-life patients, but notes legal restrictions hinder progress.
review
This review argues that while ketamine and esketamine have shifted unmet needs from acute response to post-response management, unresolved issues include durability, relapse prevention, functional recovery, patient selection, and long-term safety.
review
The within-person reduction in suicidal ideation over six months remained statistically significant after adjusting for time-varying depressive severity, indicating an anti-suicidal effect partly independent of mood improvement.
secondary analysis of a longitudinal cohort
This protocol aims to explore the acceptability, safety, and treatment preferences of psilocybin-assisted therapy in patients with bipolar II disorder struggling with suicidal ideation; no results are reported.
phase II, single-arm, open-label clinical trial feasibility study Sample size: 10
This review found inconsistent reporting practices in psilocybin-assisted therapy trials, with poor reporting of blinding success, therapist fidelity, and expectancy, and an overrepresentation of participants with previous psychedelic experiences.
systematic review
This review argues that plastogens, including ketamine and classical psychedelics, operate under an event-driven pharmacology model where transient binding induces long-lasting neuroplastic changes that outlast drug exposure.
review
Baseline depressive severity did not moderate the treatment effect of MBCT, but it moderated the indirect effect through decentering, with decentering more strongly associated with symptom reduction among those with higher baseline depression.
secondary moderation, mediation, and moderated mediation analyses of a randomized trial Sample size: 234
Psilocybin-induced c-Fos expression in the nucleus accumbens is mediated by 5-HT2A receptors in neurons and by 5-HT2B receptors in both neurons and non-neuronal cells, suggesting a role for these receptors in mood-related circuits.
experimental study
Australia's regulatory pathway for MDMA and psilocybin prescriptions has grown rapidly, with authorized prescribers increasing by over 135% within six months, though they represent about 1% of the psychiatric workforce.
review
This review states that intravenous ketamine is supported by guidelines for treatment-resistant depression but requires careful monitoring due to variable efficacy and side effects.
review
No significant differences in depressive symptom trajectories were observed between a front-loaded and a spaced interval-extension maintenance schedule for intranasal esketamine, though induction produced significant reductions.
retrospective observational cohort Sample size: 65
Both intranasal esketamine and intravenous ketamine produced large and clinically meaningful reductions in depression severity during induction therapy, with no significant between-group differences.
retrospective cohort study Sample size: 63
Ketamine combined with psychotherapy shows promising reductions in craving and increases in abstinent days for alcohol and cocaine use disorders, but effects on relapse prevention are inconsistent and the drug carries a well-established risk of misuse.
narrative review
Mindfulness-based cognitive therapy, compared to treatment as usual alone, was associated with greater integration of bodily and interoceptive processing regions within whole-brain manifolds and increased brain flexibility during rumination.
randomized controlled trial Sample size: 80
Inhaled DMT with psychological support was associated with reduced anxiety, increased life satisfaction, and sustained improvements in quality of life in patients with treatment-resistant depression over 12 months.
open-label clinical trial Sample size: 41
Points of agreement
- Ketamine and esketamine consistently show significant acute antidepressant effects in treatment-resistant depression across multiple study types.
- Psilocybin-assisted therapy shows promise for depression, but evidence is considered preliminary and requires structured psychotherapeutic support.
- Real-world studies of esketamine and ketamine report large reductions in depressive symptoms during induction, with no significant differences between the two.
- Several reviews and trials highlight the need for better long-term data on durability, relapse prevention, and safety of rapid-acting antidepressants.
Conflicts
- One RCT found no effect of oral esketamine on serum BDNF, while other research suggests BDNF increases may be a biomarker of response to intravenous ketamine.
- A Delphi panel recommended dose/frequency maximization for esketamine, but an observational study found no difference between front-loaded and spaced maintenance schedules.
- Some reviews report promising long-term effects of psychedelics, while others note inconsistent reporting and methodological limitations that may affect conclusions.
Gaps
- Durability of antidepressant effects beyond acute induction is understudied, especially for psilocybin and DMT.
- Long-term safety and abuse liability of repeated ketamine/esketamine treatment remain unresolved.
- Optimal maintenance scheduling for esketamine is unclear, with conflicting expert opinion and observational data.
- Most psychedelic trials lack adequate blinding, therapist fidelity reporting, and expectancy controls.
- Populations with bipolar disorder, suicidality, or comorbid personality disorders are often excluded from trials, limiting generalizability.
- Predictive biomarkers for treatment response are still elusive, with only preliminary neuroimaging findings.